Detection of primary clarithromycin resistance of Helicobacter pylori and association between cagA (+) status and clinical outcome
Language English Country United States Media print-electronic
Document type Journal Article
- MeSH
- Anti-Bacterial Agents pharmacology therapeutic use MeSH
- Antigens, Bacterial genetics MeSH
- Drug Resistance, Bacterial MeSH
- Bacterial Proteins genetics MeSH
- Biopsy MeSH
- DNA, Bacterial genetics isolation & purification MeSH
- Adult MeSH
- Virulence Factors genetics MeSH
- Helicobacter pylori drug effects isolation & purification pathogenicity MeSH
- Helicobacter Infections drug therapy microbiology pathology MeSH
- Clarithromycin pharmacology therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Microbial Sensitivity Tests MeSH
- Young Adult MeSH
- Polymerase Chain Reaction MeSH
- Polymorphism, Restriction Fragment Length MeSH
- Rural Population MeSH
- Treatment Outcome MeSH
- Gastric Mucosa microbiology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Turkey MeSH
- Names of Substances
- Anti-Bacterial Agents MeSH
- Antigens, Bacterial MeSH
- Bacterial Proteins MeSH
- cagA protein, Helicobacter pylori MeSH Browser
- DNA, Bacterial MeSH
- Virulence Factors MeSH
- Clarithromycin MeSH
Helicobacter pylori was examined in 110 patients (82 (74.5) with gastritis, 18 (16.4) with duodenitis, six (5.5) with duodenal ulcer and gastroesophageal reflux, and four (3.6 %) with normal) with gastrointestinal problems living in rural area, no history of macrolide use, and detected by culture (71.8) or direct detection from gastric biopsies by PCR (82.7 %). Also, cagA gene was identified using PCR and was found positive in 68/91 (74.7 %) strains. The prevalence of clarithromycin-resistant H. pylori was investigated by two methods including PCR-RFLP (7.7 (A2142G 1.1 and A2143G 6.6 %)) and twofold agar dilution (8.9 %) to detect phenotypic and genotypic status simultaneously. Among all the H. pylori positive patients, eight (8.8 %) isolates were found to be resistant to clarithromycin by at least one of the AD and/or PCR-RFLP methods. H. pylori positive rates were significantly correlated with patients' sex, age, and endoscopic findings (p = 0.040, <0.001 and <0.001, respectively). There were no differences in gender or endoscopic findings related to cagA (+) and cagA (-) patients. The gene of cagA was not significantly helpful in predicting the clinical outcome of H. pylori infection alone. In conclusion, we revealed that there was a low prevalence of primer clarithromycin resistance in patients living in rural area with no history of macrolide use. The prevalence of mutant strains among the macrolide-resistant H. pylori varies even geographically between close provinces.
See more in PubMed
J Clin Microbiol. 2012 Mar;50(3):876-83 PubMed
Int J Infect Dis. 2008 Jan;12(1):30-6 PubMed
J Clin Microbiol. 2009 Dec;47(12):4150-3 PubMed
Gut. 2002 Mar;50(3):285-9 PubMed
PLoS One. 2009 Nov 06;4(11):e7736 PubMed
J Gastroenterol. 2006 Jul;41(7):668-73 PubMed
J Gastrointestin Liver Dis. 2011 Sep;20(3):235-9 PubMed
Infect Genet Evol. 2008 Dec;8(6):815-9 PubMed
Jpn J Infect Dis. 2008 May;61(3):179-83 PubMed
Turk J Gastroenterol. 2008 Sep;19(3):163-7 PubMed
Antimicrob Agents Chemother. 1996 Feb;40(2):477-80 PubMed
Curr Ther Res Clin Exp. 2007 May;68(3):151-60 PubMed
Clin Microbiol Rev. 2001 Oct;14(4):836-71, table of contents PubMed
J Microbiol. 2006 Aug;44(4):409-16 PubMed
J Gastrointestin Liver Dis. 2010 Dec;19(4):409-14 PubMed
Clin Infect Dis. 2003 Oct 1;37(7):882-9 PubMed
Folia Microbiol (Praha). 2010 Nov;55(6):649-56 PubMed
Helicobacter. 2006 Dec;11(6):574-80 PubMed
Gut. 1998 Sep;43(3):317-21 PubMed
J Clin Microbiol. 2004 Apr;42(4):1648-51 PubMed
J Clin Gastroenterol. 2007 Sep;41(8):747-50 PubMed
Gut. 2007 Jun;56(6):772-81 PubMed
Gastroenterology. 1998 Mar;114(3):579-81 PubMed
Cancer Epidemiol. 2011 Oct;35(5):e32-7 PubMed
